AMAG Pharmaceuticals
AMAG
AMAG was delisted on the 13th of November, 2020.
102 hedge funds and large institutions have $478M invested in AMAG Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 34 increasing their positions, 30 reducing their positions, and 23 closing their positions.
252% more call options, than puts
Call options by funds: $6.07M | Put options by funds: $1.72M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
15.39% more ownership
Funds ownership: 97.89% → 113.29% (+15%)
13% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 30
5% less funds holding
Funds holding: 107 → 102 (-5)
8% less capital invested
Capital invested by funds: $518M → $478M (-$40.2M)
17% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
+$42.5M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$36M |
| 3 |
BC
Broadfin Capital
New York
|
+$18.4M |
| 4 |
State Street
Boston,
Massachusetts
|
+$13.7M |
| 5 |
Millennium Management
New York
|
+$13.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$25.1M |
| 2 |
First Manhattan
New York
|
-$15.4M |
| 3 |
JP Morgan Chase
New York
|
-$15.2M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$10.1M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$6.85M |
AMAG Hedge Fund Activity: Q1 2014 in Review
102 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in AMAG Pharmaceuticals (AMAG) for Q1 2014, worth a combined $478M — down 7.8% from $518M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of AMAG and 19 opened new positions — a net loss of 4 holders — while 30 trimmed existing stakes and 34 added.
The largest buyer was Visium Asset Management, opening a new position worth an estimated $42.5M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $25.1M sold.
- 102 institutional investors held AMAG Pharmaceuticals (AMAG) as of Q1 2014, down from 107 in Q4 2013.
- Funds reported $478M of AMAG Pharmaceuticals stock for Q1 2014, down 7.8% quarter-over-quarter.
- 19 funds opened new AMAG Pharmaceuticals positions in Q1 2014 and 23 closed out, a net change of -4 holders.
- The largest AMAG Pharmaceuticals buyer in Q1 2014 was Visium Asset Management, an estimated $42.5M added.
- The largest AMAG Pharmaceuticals seller in Q1 2014 was Consonance Capital Management, an estimated $25.1M sold.
Based on aggregated 13F filings for Q1 2014.